Back to top

Image: Bigstock

Nabriva Therapeutics (NBRV) in Focus: Stock Moves 7.5% Higher

Read MoreHide Full Article

Nabriva Therapeutics plc (NBRV - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.1300 –$3.1700 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Nabriva Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Nabriva Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.  

Nabriva Therapeutics AG Price

Investors interested in the Medical – Biomedical and Genetics industry may consider Celcuity Inc. (CELC - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is NBRV going up? Or down? Predict to see what others think:Up or Down

Today's Best Stocks from Zacks
 
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
 
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Nabriva Therapeutics AG (NBRV) - free report >>

Celcuity, Inc. (CELC) - free report >>

More from Zacks Tale of the Tape

You May Like